Sio Gene Therapies
New York
About Sio Gene Therapies
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $204.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2020)
- Ticker: nasdaq:AXGT
- Website: siogtx.com
- Phone: 833-296-8268
Industries & Categories
Biopharma, Biotechnology, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sio-gene-therapies-188846 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.